Clinical Trials Logo

Stage III Melanoma clinical trials

View clinical trials related to Stage III Melanoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04703426 Withdrawn - Metastatic Melanoma Clinical Trials

Sargramostim (GM-CSF) + PD-1

Start date: April 16, 2021
Phase: Phase 2
Study type: Interventional

This research study is testing the combination of two drugs, sargramostim and pembrolizumab. The study is designed to see if the combination of these study drugs would improve the control of unresectable or metastatic melanoma cancer when compared to use of these drugs alone. The names of the study drugs involved in this study are: - Pembrolizumab - Sargramostim (GM-CSF)

NCT ID: NCT01851408 Withdrawn - Melanoma Clinical Trials

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Start date: April 2006
Phase: Phase 2
Study type: Interventional

This phase II portion of the trial is studying the side effects and best dose of temsirolimus when given together with sorafenib and to see how well they work in treating patients with metastatic, recurrent, or unresectable melanoma. Sorafenib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with temsirolimus may kill more tumor cells.